Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

NCT04377503 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

OTHER

Sponsor class

Stopped The number of critically ill patients wirh COVID-19 decrease abruptly

Conditions

Cytokine Release Syndrome
Covid-19

Interventions

DRUG: Tocilizumab 180 MG/ML
DRUG: Methylprednisolone Sodium Succinate

Sponsor

Hospital Sao Domingos